Mabion SA Sustainability Reports

Mabion S.A. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of biotherapeutics. The company operates based on monoclonal antibody technology to produce biological medicines and biosimilars.

Sector: Manufacturing

Country: Poland

Exchange: Warsaw Stock Exchange

LEI: 259400KG5JVQPPZL6X53

FIGI: BBG001T8RDF4

11 reports from 2019 to 2025

• Mabion SA 2025 Directors' Report
• Mabion SA 2025 ESG Report
• Mabion SA 2025 Financial Statements
• Mabion SA 2024 Financial Statements for the Financial Year Ended 31 December
• Mabion SA 2024 ESG Report